
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences, Inc. is projected to experience significant sales growth, with estimates reaching approximately $225 million in 2032, reflecting a 60% probability of success for its lead programs. The company’s CGT9486 program has demonstrated favorable outcomes in initial trials compared to historical controls, indicating strong potential in treating Systemic Mastocytosis and advanced gastrointestinal stromal tumors. Additionally, the competitive profile of Bezuclastinib against existing therapies suggests the possibility of capturing meaningful market share, further enhancing the company's financial outlook.
Bears say
The financial outlook for Cogent Biosciences Inc is negatively impacted by several key risks, including the potential for unfavorable clinical data, slower-than-expected timelines in clinical development, and the possibility of setbacks in regulatory approvals. Notably, there are concerns regarding the safety profile of bezuclastinib in non-advanced systemic mastocytosis, which could hinder its market adoption despite its efficacy. Furthermore, projections for commercial success have been adjusted downward, as indicated by a significant revision in peak market penetration estimates for its therapies from 50% to 20%, reflecting increased competition and a more cautious market landscape.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares